Peptides · Peptide comparison
Abarelix vs Degarelix
GnRH Antagonist for Advanced Prostate Cancer Treatment
Fast-acting GnRH antagonist that rapidly lowers testosterone for advanced prostate cancer treatment
- Hormone Support
- Hormone Support
At a glance
Quick comparison
Dose rangeAbarelix100–100 mgDegarelix80–80 mg
FrequencyAbarelixOnce dailyDegarelixOnce daily
AdministrationAbarelixIntramuscular injection (depot formulation)DegarelixAs directed by healthcare provider
Cycle lengthAbarelixOngoing/indefiniteDegarelixOngoing/indefinite
Onset speedAbarelixModerate (1-2 weeks)DegarelixModerate (1-2 weeks)
Evidence levelAbarelixStrong human trials (Phase 3 or FDA approved)DegarelixStrong human trials (Phase 3 or FDA approved)
Efficacy
Benefit ratings
Rapid Hormone Control
Advanced Cancer Management
Patient Tolerability
Rapid Testosterone Control
Extended Duration
Clinical Efficacy
Technical data
Compound specifications
Abarelix
- Molecular formula
- C72H95ClN14O14
- Molecular weight
- 1416.1 g/mol
- Half-life
- Approximately 13 days
- Bioavailability
- ~100% (intramuscular depot injection)
- CAS number
- 183552-38-7
Degarelix
- Molecular formula
- C82H103ClN18O16
- Molecular weight
- 1632.3 Da
- Half-life
- ~53 days (median terminal half-life)
- Bioavailability
- 100% (subcutaneous injection)
- CAS number
- 214766-78-6
Protocols
Dosing compared
Abarelix
Intramuscular
- 100 mgDay 1, 15, 29, then every 4 weeks · Up to 12 months (effectiveness beyond 12 months not established)This is the FDA-approved dose for advanced prostate cancer. A 100 mg shot is given into the buttock muscle on day 1, 15, and 29, then once every 4 weeks. The drug was sold as Plenaxis. [4]
Degarelix
Subcutaneous
- 240 mg (two 120 mg injections)One time (loading dose) · Single starting doseFDA-approved loading dose for advanced prostate cancer, given as two separate deep injections under the skin of the belly. This rapidly lowers testosterone without the early surge seen with older drugs [1][2].
- 80 mgEvery 28 days · OngoingFDA-approved maintenance dose, started 28 days after the loading dose. Keeps testosterone at castrate levels in over 97% of patients [1][2].
Applications
Best suited for
Abarelix
- Reducing testosterone levels in prostate cancer
- Abarelix is particularly well-suited for individuals focused on reducing testosterone levels in prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Slowing cancer progression in advanced disease
- Abarelix is particularly well-suited for individuals focused on slowing cancer progression in advanced disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Managing hormone-dependent cancer symptoms
- Abarelix is particularly well-suited for individuals focused on managing hormone-dependent cancer symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Degarelix
- Men with advanced or metastatic prostate cancer requiring rapid hormone control
- Degarelix is particularly well-suited for individuals focused on men with advanced or metastatic prostate cancer requiring rapid hormone control. [1][2] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Patients who need immediate testosterone suppression to prevent cancer progression
- Degarelix is particularly well-suited for individuals focused on patients who need immediate testosterone suppression to prevent cancer progression. [1][2] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Men who cannot tolerate the initial testosterone surges from GnRH agonists
- Degarelix is particularly well-suited for individuals focused on men who cannot tolerate the initial testosterone surges from gnrh agonists. [5][6] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety profile
Side effects
Abarelix
Common
- Mild discomfort at treatment site
- Hot flashes and sweating
- Decreased libido and sexual dysfunction
- Increased liver enzymes
- Injection site reactions (pain, redness, swelling)
- Abdominal pain and gastrointestinal symptoms
- Headache and dizziness
- Weight changes
- Gynecomastia (breast tissue enlargement)
- Bone density loss with long-term use
Serious
- Severe allergic reaction
Degarelix
Common
- Mild discomfort at treatment site
- Injection site pain (28% of patients)
- Injection site redness or erythema (17%)
- Hot flashes (26% experience them)
- Increased liver enzymes and gamma-glutamyltransferase (10%)
- Weight gain (9%)
- Hypertension or elevated blood pressure (6%)
- Back pain (6%)
- Chills (5%)
- Constipation (5%)
- Urinary tract infection (5%)
- Injection site swelling (6%)
- Injection site induration or hardness (4%)
- Decreased sex drive and erectile dysfunction
- Gynecomastia (breast tissue growth)
- Testicular atrophy (shrinking)
Serious
- Severe allergic reaction
Research status
Safety & evidence
Abarelix
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved in 2003 as PLENAXIS for advanced symptomatic prostate cancer; discontinued and no longer marketed in the US.
- Safety overview
- Abarelix carries significant safety concerns primarily related to histamine release reactions, which led to its voluntary withdrawal from the U.S. market in 2006. Serious allergic responses including anaphylaxis, flushing, and hypotension have been documented. Long-term use poses substantial risks of bone density loss, cardiovascular effects from hormonal suppression, and metabolic complications including weight gain and altered lipid profiles. Liver enzyme elevations occur in 5-10% of patients. All use requires intensive medical supervision with regular monitoring of testosterone levels, liver function, bone density, and cardiovascular markers.
Contraindications
- Pregnancy or lactation
- Severe hypersensitivity reactions to peptide therapeutics
- History of anaphylaxis with similar compounds
Degarelix
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Degarelix is an FDA-approved GnRH antagonist with safety data from Phase 3 trials and post-market use in prostate cancer treatment. [1][2] Advantages over GnRH agonists include absence of testosterone flare, allowing rapid castration without initial symptom surge. [5][6] Primary safety concerns relate to intentional hormone suppression: hot flashes occur in 40-70% of men, erectile dysfunction in 40-60%, bone density loss of 2-3% annually, [8] and cardiovascular risks in patients >65 years. [9] Injection site reactions (erythema, induration) occur in 20-30% of patients and can be severe in a small percentage. [2] Liver enzyme elevations appear in 5% of patients. [2] QT prolongation potential exists and cardiac monitoring is recommended in susceptible patients. [2]
Contraindications
- History of severe hypersensitivity to degarelix [2]
- Allergy to any product components (mannitol or other additives) [2]
- Active untreated severe anaphylaxis risk
Decision guide
Which is right for you?
Abarelix
Choose Abarelix if…
- Reducing testosterone levels in prostate cancer
- Slowing cancer progression in advanced disease
- Managing hormone-dependent cancer symptoms
Degarelix
Choose Degarelix if…
- Men with advanced or metastatic prostate cancer requiring rapid hormone control
- Patients who need immediate testosterone suppression to prevent cancer progression
- Men who cannot tolerate the initial testosterone surges from GnRH agonists